Jennifer Buell - Jan 18, 2024 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
Chief Executive Officer
Signature
By: /s/ Christine Klaskin, Attorney-in-Fact for Jennifer S. Buell
Stock symbol
INKT
Transactions as of
Jan 18, 2024
Transactions value $
$0
Form type
4
Date filed
1/18/2024, 08:00 PM
Previous filing
Oct 13, 2023
Next filing
Mar 29, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INKT Stock Option Award $0 +500K $0.00 500K Jan 16, 2024 Common Stock 500K $0.87 Direct F1
transaction INKT Stock Option Award $0 +661K $0.00 661K Jan 16, 2024 Common Stock 661K $0.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 An option to purchase Common Stock was granted to Dr. Buell on January 16, 2024 and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the grant date, with the remainder vesting in equal quarterly installments thereafter.
F2 An option to purchase Common Stock was granted to Dr. Buell on January 16, 2024 for her performance in 2023, and awarded in accordance with the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan. Half of the options will vest on June 27, 2024 and half of the options will vest on September 27, 2024